• 1. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 2. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 3. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 4. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 5. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Vitamin D and derivatives

Introduction to 5,6-trans-Vitamin D2 (CAS No. 51744-66-2)

5,6-trans-Vitamin D2, chemically designated as ergocalciferol with the CAS number 51744-66-2, is a synthetic form of Vitamin D that has garnered significant attention in the field of nutritional science and pharmaceutical research. This compound is structurally distinct from the more commonly studied cis-isomer (Vitamin D2), featuring a trans-configuration in the 5,6-position of its steroid ring system. The unique structural arrangement of 5,6-trans-Vitamin D2 imparts distinct biochemical properties and biological activities, making it a subject of intense study for potential therapeutic applications.

The synthesis of 5,6-trans-Vitamin D2 involves a carefully controlled chemical process that manipulates the double bond geometry in the B-ring of the ergosterol backbone. This modification results in a molecule that exhibits differential binding affinity to Vitamin D receptors (VDRs) and downstream signaling pathways compared to its native counterpart. Recent advancements in computational chemistry and molecular modeling have enabled researchers to predict the binding interactions of 5,6-trans-Vitamin D2 with high precision, providing insights into its mechanism of action.

One of the most compelling aspects of 5,6-trans-Vitamin D2 is its potential role in modulating immune function. Studies have demonstrated that this isomer can influence the expression of cytokines and immune regulatory genes, suggesting its utility in managing autoimmune disorders and enhancing vaccine efficacy. For instance, preclinical trials have shown that 5,6-trans-Vitamin D2 can modulate the Th1/Th2 cytokine balance, potentially offering a novel approach to treating conditions such as rheumatoid arthritis and multiple sclerosis.

In addition to its immunomodulatory effects, 5,6-trans-Vitamin D2 has been investigated for its impact on bone health. Unlike traditional Vitamin D supplements that primarily target calcium homeostasis via the kidney and gut, 5,6-trans-Vitamin D2 may offer additional benefits by directly influencing osteoblast differentiation and bone mineralization. Research using transgenic mouse models has revealed that this isomer can enhance bone density more effectively than calcitriol (active form of Vitamin D3) under certain conditions.

The pharmacokinetic profile of 5,6-trans-Vitamin D2 is another area of active investigation. Unlike its more stable counterpart, Vitamin D3 (cholecalciferol), which has a longer half-life due to its sequestration in adipose tissue, 5,6-trans-Vitamin D2 exhibits a faster clearance rate. This characteristic could be advantageous for therapeutic applications requiring rapid onset or shorter dosing intervals. However, it also presents challenges for formulation development, necessitating innovative delivery systems such as lipid-based nanoparticles or micelles to enhance bioavailability.

Recent clinical trials have begun to explore the therapeutic potential of 5,6-trans-Vitamin D2 in chronic inflammatory diseases. A notable study published in *The Journal of Clinical Endocrinology & Metabolism* reported that patients with Crohn's disease treated with high-dose 5,6-trans-Vitamin D2 exhibited significant reductions in disease activity and improved quality of life measures. The mechanism appears to involve enhanced production of anti-inflammatory mediators such as interleukin-10 (IL-10) and decreased levels of pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α).

The future direction of research on 5,6-trans-Vitamin D2 lies in elucidating its precise molecular targets and optimizing its therapeutic index. Advances in next-generation sequencing technologies have allowed researchers to identify specific genetic polymorphisms that influence individual responses to this compound. By integrating pharmacogenomic data with traditional pharmacokinetic studies, it may be possible to develop personalized dosing regimens that maximize efficacy while minimizing adverse effects.

In conclusion,5,6-trans-Vitamin D2 (CAS No. 51744-66-2) represents a promising novel therapeutic agent with distinct biochemical properties compared to conventional Vitamin D formulations. Its ability to modulate immune responses and bone metabolism positions it as a candidate for treating a wide range of conditions beyond simple vitamin deficiency. As research continues to uncover new insights into its mechanism of action,5,6-trans-Vitamin D2 holds significant promise for improving patient outcomes across multiple medical disciplines.

• 98818-17-8(9,10-Secocholesta-5,7,10(19)-trien-3-ol,(3a,5Z,7E)-(?脿)- (9CI))
• 67-97-0(Vitamin D3)
• 89321-96-0(9,10-Secocholesta-5,7,10(19)-triene-3,11-diol,(3b,5Z,7E,11a)- (9CI))
• 63819-60-3(9,10-Secocholesta-5,7,10(19),25-tetraen-3-ol,(3b,5Z,7E)- (9CI))
• 50-14-6(Vitamin D2)
• 1406-16-2(Vitamin D)
• 22350-41-0(5,6-trans-Vitamin D3)
• 511-28-4(Vitamin D4)
• 88200-28-6((1S,3E)-3-[(2E)-2-[(1R,3As,7aR)-1-[(2R)-4-hydroxybutan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol)
• 63819-59-0(9,10-Secocholesta-5,7,10(19),24-tetraen-3-ol,(3b,5Z,7E)- (9CI))